Eikon Therapeutics Files 8-K on Financials
Ticker: EIKN · Form: 8-K · Filed: Mar 30, 2026 · CIK: 0001861123
| Field | Detail |
|---|---|
| Company | Eikon Therapeutics, INC. (EIKN) |
| Form Type | 8-K |
| Filed Date | Mar 30, 2026 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-results, 8-k
TL;DR
Eikon Therapeutics dropped its 8-K. Check financials.
AI Summary
Eikon Therapeutics, Inc. filed an 8-K on March 30, 2026, reporting on its financial condition and results of operations. The filing includes financial statements and exhibits, with the primary document being an iXBRL 8-K.
Why It Matters
This filing provides investors with crucial updates on Eikon Therapeutics' financial performance and operational status as of March 30, 2026.
Risk Assessment
Risk Level: low — This is a routine filing of financial results and exhibits, not indicating any immediate or significant risk.
Key Players & Entities
- Eikon Therapeutics, Inc. (company) — Filer
- 0001861123 (company) — CIK Number
- 2026-03-30 (date) — Filing Date and Period of Report
FAQ
What specific financial results are reported in this 8-K filing?
The filing indicates Item 2.02: Results of Operations and Financial Condition, but the specific financial figures are detailed within the attached documents, such as the iXBRL 8-K.
What is the purpose of the EX-99.1 document mentioned?
EX-99.1 is listed as an exhibit to the 8-K filing, typically containing supplementary information or financial statements.
When was this 8-K filing accepted by the SEC?
The filing was accepted on March 30, 2026, at 08:02:06.
What is Eikon Therapeutics' primary business according to the SIC code?
The SIC code 2836 indicates that Eikon Therapeutics is involved in Biological Products, (No Diagnostic Substances).
Where is Eikon Therapeutics located?
The company's mailing and business address is 230 HARRIET TUBMAN WAY, MILLBRAE, CA 94030.
Filing Stats: 548 words · 2 min read · ~2 pages · Grade level 9.2 · Accepted 2026-03-30 08:02:06
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share EIKN The Nasdaq
Filing Documents
- d244624d8k.htm (8-K) — 26KB
- d244624dex991.htm (EX-99.1) — 37KB
- 0001193125-26-130449.txt ( ) — 182KB
- eikn-20260330.xsd (EX-101.SCH) — 3KB
- eikn-20260330_lab.xml (EX-101.LAB) — 18KB
- eikn-20260330_pre.xml (EX-101.PRE) — 11KB
- d244624d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. EXHIBIT NUMBER EXHIBIT DESCRIPTION 99.1 Press Release, dated March 30, 2026. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Eikon Therapeutics, Inc. By: /s/ Roger M. Perlmutter, M.D., Ph.D. Roger M. Perlmutter, M.D., Ph.D. Chief Executive Officer Dated: March 30, 2026